EORTC-NCI-AACR 2010: A Phase 1b Study of Escalating Doses of Vascular Endothelial Growth Factor (VEGF) Tyrosine Kinase Inhibitor Tivozanib and FOLFOX6 in Patients With Advanced Gastrointestinal (GI) Tumors
TIVO-3: Final OS Analysis Of A Phase III, Randomized, Controlled, Multicenter, Open-Label Study To Compare Tivozanib To Sorafenib In Subjects With Metastatic Renal Cell Carcinoma (RCC)
